Academic Journal
Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials.
| Τίτλος: | Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials. |
|---|---|
| Συγγραφείς: | Gamrath L; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark., Pedersen TB; Department of Clinical Diagnostics, University Hospital of Southern Denmark, Esbjerg, Denmark., Møller MV; Department of Clinical Diagnostics, University Hospital of Southern Denmark, Esbjerg, Denmark., Volmer LM; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark.; Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark., Holst-Christensen L; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark., Vestermark LW; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark., Donskov F; Department of Oncology, University Hospital of Southern Denmark, Finsensgade 35, Esbjerg, 6700, Denmark. fdonskov@health.sdu.dk.; Department of Regional Health Science, University of Southern Denmark, Odense, Denmark. fdonskov@health.sdu.dk. |
| Πηγή: | Current oncology reports [Curr Oncol Rep] 2025 Jan; Vol. 27 (1), pp. 45-58. Date of Electronic Publication: 2025 Jan 03. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Philadelphia, PA : Current Science, c1999- |
| Ιατρικοί όροι (MeSH): | Neoplasms*/drug therapy , Immune Checkpoint Inhibitors*/therapeutic use , Immunotherapy* , Gastrointestinal Microbiome*, Bacteria/classification ; Clinical Trials as Topic ; Humans ; Diet ; Metabolome |
| Περίληψη: | Purpose of Review: The advent of checkpoint immunotherapy has dramatically changed the outcomes for patients with cancer. However, a considerable number of patients have little or no response to therapy. We review recent findings on the connection between the gut microbiota and the immune system, exploring whether this link could enhance the effectiveness of immunotherapy. Recent Findings: Clinical studies have reported specific types of bacteria in larger quantities at baseline in responders than in non-responders, especially Akkermansia mucinifila, Ruminococcaceae, Faecalibacterium, and Lachnospiraceae. Following the consumption of a high-fiber diet, bacteria in the gut ferment dietary fiber to short-chain fatty acids (SCFAs), like acetate, propionate, and butyrate. Some of the SCFAs nurture intestinal epithelial cells, and some enter the bloodstream. Here SCFAs can activate DC8 + cytotoxic T-cells to induce cancer cell death. High fiber intake in the diet was associated with a reduced risk of progression or death during checkpoint immunotherapy. Recent findings demonstrate that high-fiber plant-based diets such as the Mediterranean Diet positively influence the gut microbiota whereas antibiotics and proton pump inhibitors can negatively influence outcomes of cancer immunotherapy by changing the gut microbiota. This narrative review provides evidence of an association between types of bacteria and their metabolites and favorable responses to checkpoint immunotherapy. Prospective clinical trials are needed to determine if diet interventions can improve treatment outcomes. (© 2024. The Author(s).) |
| Competing Interests: | Declarations. Competing Interests: The authors do not have any potential conflicts of interest to disclose. Human and Animal Rights and Informed Conse: As this was a review paper, no human or animal research was conducted by the authors. |
| References: | Nature. 2019 Jan;565(7741):600-605. (PMID: 30675064) Science. 2024 Apr 26;384(6694):428-437. (PMID: 38662827) Science. 2018 Jan 5;359(6371):104-108. (PMID: 29302014) Adv Immunol. 2014;121:91-119. (PMID: 24388214) Lancet Gastroenterol Hepatol. 2019 Dec;4(12):984-996. (PMID: 31696832) J Immunother Cancer. 2019 Jul 23;7(1):193. (PMID: 31337439) J Clin Med. 2022 Sep 18;11(18):. (PMID: 36143126) Nat Commun. 2024 Aug 21;15(1):7187. (PMID: 39168966) ISME J. 2017 Apr;11(4):841-852. (PMID: 28045459) Nutr Cancer. 2023;75(5):1349-1360. (PMID: 36942399) Cancer. 2023 Jul 1;129(13):2047-2055. (PMID: 37089083) J Immunother Cancer. 2021 Dec;9(12):. (PMID: 34873013) J Cancer Res Clin Oncol. 2023 Jan;149(1):541-552. (PMID: 36550389) Ann Pharmacother. 2022 Apr;56(4):377-386. (PMID: 34282636) Nature. 2020 Apr;580(7802):269-273. (PMID: 32106218) Cancer Biol Med. 2021 May 07;:. (PMID: 33960176) Science. 2021 Dec 24;374(6575):1632-1640. (PMID: 34941392) Nature. 2010 Mar 4;464(7285):59-65. (PMID: 20203603) Genome Med. 2022 Mar 29;14(1):35. (PMID: 35346337) Nat Med. 2022 Mar;28(3):545-556. (PMID: 35228752) mSystems. 2018 May 15;3(3):. (PMID: 29795809) Biomark Res. 2024 Jun 3;12(1):56. (PMID: 38831368) J Prev Med Hyg. 2022 Oct 17;63(2 Suppl 3):E36-E43. (PMID: 36479477) Int J Mol Sci. 2017 Dec 07;18(12):. (PMID: 29215589) Cell. 2005 Dec 16;123(6):975-6. (PMID: 16360024) Cancer Med. 2023 Mar;12(5):6325-6336. (PMID: 36205311) Oncol Ther. 2021 Dec;9(2):647-657. (PMID: 34664203) Melanoma Res. 2020 Jun;30(3):235-246. (PMID: 31990790) Gut Microbes. 2023 Dec;15(2):2249143. (PMID: 37635362) Int J Syst Evol Microbiol. 2021 Oct;71(10):. (PMID: 34694987) Thorac Cancer. 2024 May;15(14):1149-1163. (PMID: 38572783) Front Immunol. 2023 Jan 26;14:1070076. (PMID: 36776847) Science. 2011 Oct 7;334(6052):105-8. (PMID: 21885731) ISME J. 2012 Aug;6(8):1449-58. (PMID: 22437156) Thorac Cancer. 2020 Jun;11(6):1621-1632. (PMID: 32329229) Science. 2020 May 29;368(6494):973-980. (PMID: 32467386) Nat Rev Microbiol. 2021 Jan;19(1):55-71. (PMID: 32887946) Eur Urol. 2020 Aug;78(2):195-206. (PMID: 32376136) Science. 2018 Jan 5;359(6371):97-103. (PMID: 29097493) Eur Urol. 2020 Oct;78(4):498-502. (PMID: 32828600) Clin Transl Med. 2023 Jul;13(7):e1312. (PMID: 37381590) BMJ. 2022 Jul 20;378:e054370. (PMID: 35858693) J Immunother. 2023 Nov 6;:. (PMID: 37937583) Front Oncol. 2022 Apr 21;12:837525. (PMID: 35530307) Anticancer Res. 2021 Oct;41(10):4985-4993. (PMID: 34593446) Front Immunol. 2020 Jun 09;11:906. (PMID: 32582143) FEMS Microbiol Ecol. 2008 Dec;66(3):505-15. (PMID: 18616586) Cancer Immunol Res. 2020 Oct;8(10):1251-1261. (PMID: 32855157) Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494) Ann Transl Med. 2022 Mar;10(6):325. (PMID: 35433940) J Exp Zool B Mol Dev Evol. 2020 May;334(3):149-155. (PMID: 32039567) PLoS Biol. 2016 Aug 19;14(8):e1002533. (PMID: 27541692) Front Microbiol. 2019 Oct 24;10:2410. (PMID: 31708890) Eur J Cancer. 2021 Nov;157:474-484. (PMID: 34649118) Neoplasia. 2022 Oct;32:100822. (PMID: 35908379) Nat Rev Cancer. 2013 Nov;13(11):800-12. (PMID: 24132111) AMB Express. 2022 Jul 6;12(1):86. (PMID: 35792976) Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204) Neoplasia. 2017 Oct;19(10):848-855. (PMID: 28923537) Nat Med. 2023 Aug;29(8):2121-2132. (PMID: 37414899) Cancers (Basel). 2022 Apr 16;14(8):. (PMID: 35454932) Eur J Clin Nutr. 2024 Jun;78(6):463-476. (PMID: 38459161) Cancer Immunol Res. 2020 Oct;8(10):1243-1250. (PMID: 32847937) Cancers (Basel). 2022 Oct 31;14(21):. (PMID: 36358789) Oncoimmunology. 2022 May 27;11(1):2081010. (PMID: 35655708) Anaerobe. 2017 Feb;43:56-60. (PMID: 27940244) Ann Oncol. 2019 Oct 1;30(10):1572-1579. (PMID: 31268133) J Thorac Oncol. 2019 Aug;14(8):1378-1389. (PMID: 31026576) Front Oncol. 2023 Apr 11;13:1144534. (PMID: 37114123) |
| Contributed Indexing: | Keywords: Cancer Immunotherapy; Dietary fiber; Gut Microbiota; Mediterranean Diet; Short-chain Fatty Acids |
| Substance Nomenclature: | 0 (Immune Checkpoint Inhibitors) |
| Entry Date(s): | Date Created: 20250103 Date Completed: 20250723 Latest Revision: 20250723 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11762419 |
| DOI: | 10.1007/s11912-024-01622-6 |
| PMID: | 39753816 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!